
AC Immune SA – NASDAQ:ACIU
AC Immune SA stock price today
AC Immune SA stock price monthly change
AC Immune SA stock price quarterly change
AC Immune SA stock price yearly change
AC Immune SA key metrics
Market Cap | 264.15M |
Enterprise value | 150.93M |
P/E | -2.31 |
EV/Sales | 38.35 |
EV/EBITDA | -2.21 |
Price/Sales | 42.93 |
Price/Book | 0.99 |
PEG ratio | -0.18 |
EPS | -0.61 |
Revenue | N/A |
EBITDA | -53.92M |
Income | -54.58M |
Revenue Q/Q | N/A |
Revenue Y/Y | 276.13% |
Profit margin | -1798.12% |
Oper. margin | -1800.48% |
Gross margin | 0% |
EBIT margin | -1800.48% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAC Immune SA stock price history
AC Immune SA stock forecast
AC Immune SA financial statements
Jun 2023 | 0 | -16.83M | |
---|---|---|---|
Sep 2023 | 0 | -15.14M | |
Dec 2023 | 14.80M | -4.74M | -32.05% |
Mar 2024 | 0 | -17.86M |
Sep 2023 | 0 | -15.14M | |
---|---|---|---|
Dec 2023 | 14.80M | -4.74M | -32.05% |
Mar 2024 | 0 | -17.86M | |
Dec 2025 | 171.94M | 0 |
Analysts Price target
Financials & Ratios estimates
2023-04-27 | -0.25 | -0.25 |
---|
Jun 2023 | 156228000 | 16.9M | 10.82% |
---|---|---|---|
Sep 2023 | 142986000 | 17.32M | 12.11% |
Dec 2023 | 182814000 | 22.17M | 12.13% |
Mar 2024 | 167281000 | 22.6M | 13.51% |
Jun 2023 | -14.11M | -5.15M | 1.91M |
---|---|---|---|
Sep 2023 | -13.3M | 4.72M | 448K |
Dec 2023 | -16.19M | 23.28M | 41.02M |
Mar 2024 | 1.02M | -23.56M | -688K |
AC Immune SA alternative data
Aug 2023 | 126 |
---|---|
Sep 2023 | 126 |
Oct 2023 | 126 |
Nov 2023 | 126 |
Dec 2023 | 126 |
Jan 2024 | 126 |
Feb 2024 | 126 |
Mar 2024 | 133 |
Apr 2024 | 133 |
May 2024 | 133 |
Jun 2024 | 133 |
Jul 2024 | 133 |
AC Immune SA other data
Patent |
---|
Grant Filling date: 5 Jun 2020 Issue date: 30 Aug 2022 |
Application Filling date: 20 May 2020 Issue date: 21 Jul 2022 |
Grant Filling date: 9 Oct 2020 Issue date: 7 Jun 2022 |
Application Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates Filling date: 29 Jan 2020 Issue date: 28 Apr 2022 |
Grant Filling date: 22 Jan 2019 Issue date: 19 Apr 2022 |
Application Filling date: 4 Jan 2019 Issue date: 27 Jan 2022 |
Application Filling date: 19 Aug 2021 Issue date: 16 Dec 2021 |
Application Filling date: 3 Dec 2020 Issue date: 28 Oct 2021 |
Grant Filling date: 24 Oct 2018 Issue date: 21 Sep 2021 |
Application Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates Filling date: 30 May 2019 Issue date: 2 Sep 2021 |
Insider | Compensation |
---|---|
Dr. Andrea Pfeifer (1957) Co-Founder, Chief Executive Officer & Director | $1,140,000 |
AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts
AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures
Organigram And Rounding Out My Tax Loss Selling Basket
Why I've Added A Full Position In AC Immune To My Tax Loss Selling Basket
Johnson & Johnson: Alzheimer's Disease Pipeline Could Dominate
AC Immune: Old Theory, New Company
-
What's the price of AC Immune SA stock today?
One share of AC Immune SA stock can currently be purchased for approximately $2.2.
-
When is AC Immune SA's next earnings date?
Unfortunately, AC Immune SA's (ACIU) next earnings date is currently unknown.
-
Does AC Immune SA pay dividends?
No, AC Immune SA does not pay dividends.
-
How much money does AC Immune SA make?
AC Immune SA has a market capitalization of 264.15M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 276.14% to 14.8M US dollars. AC Immune SA made a loss 54.23M US dollars in net income (profit) last year or -$0.25 on an earnings per share basis.
-
What is AC Immune SA's stock symbol?
AC Immune SA is traded on the NASDAQ under the ticker symbol "ACIU".
-
What is AC Immune SA's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of AC Immune SA?
Shares of AC Immune SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AC Immune SA's key executives?
AC Immune SA's management team includes the following people:
- Dr. Andrea Pfeifer Co-Founder, Chief Executive Officer & Director(age: 68, pay: $1,140,000)
-
Is AC Immune SA founder-led company?
Yes, AC Immune SA is a company led by its founder Dr. Andrea Pfeifer.
-
How many employees does AC Immune SA have?
As Jul 2024, AC Immune SA employs 133 workers.
-
When AC Immune SA went public?
AC Immune SA is publicly traded company for more then 8 years since IPO on 23 Sep 2016.
-
What is AC Immune SA's official website?
The official website for AC Immune SA is acimmune.com.
-
How can i contact AC Immune SA?
AC Immune SA can be reached via phone at +41 21 345 91 21.
AC Immune SA company profile:

AC Immune SA
acimmune.comNASDAQ
133
Biotechnology
Healthcare
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Lausanne, 1015
CIK: 0001651625
ISIN: CH0329023102
CUSIP: H00263105